Related Experiment Video

Updated: Mar 8, 2026

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

7.1K

MicroRNA in breast cancer: The association with BRCA1/2

Nina Petrovic, Radoslav Davidovic, Vladan Bajic

    Cancer Biomarkers : Section a of Disease Markers
    |January 28, 2017
    PubMed

    Insights

    MicroRNAs (miRNAs) regulate Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) genes, influencing tumor development and therapy outcomes. Understanding these interactions is key for novel breast cancer treatments.

    Area of Science:

    • Oncology
    • Genetics
    • Molecular Biology

    Background:

    • Breast cancer (BC) is a complex disease requiring innovative research and therapies.
    • Breast cancer 1 (BRCA1) and Breast cancer 2 (BRCA2) proteins are crucial tumor suppressors with therapeutic potential.
    • MicroRNAs (miRNAs) are emerging as key regulators in BC pathogenesis.

    Purpose of the Study:

    • To review the intricate network of miRNAs and their relationship with BRCA1/2 in breast cancer.
    • To explore how these interactions impact the development and treatment of specific BC subtypes.
    • To highlight potential therapeutic strategies based on miRNA-BRCA1/2 pathways.

    Main Methods:

    • Literature review of recent studies on miRNA and BRCA1/2 in breast cancer.
    • Analysis of miRNA targeting of BRCA1 and its functional consequences.
    • Discussion of the role of specific miRNAs in BC subtypes like triple-negative BC (TNBC).

    Main Results:

    • BRCA1 is targeted by numerous miRNAs, with some (e.g., miR-155, miR-146a) potentially repressing its activity.
    • Downregulation of BRCA1 by miRNAs (e.g., miR-15/107/182) can impair DNA repair and affect therapy.
    • Specific miRNAs (e.g., miR-21, miR-342) show potential for targeted therapies in BRCA2 mutation carriers or via synthetic lethality.

    Conclusions:

    • The interplay between miRNAs and BRCA1/2 is critical for understanding BC heterogeneity and progression.
    • Targeting miRNA-BRCA1/2 pathways offers promising avenues for novel therapeutic approaches, particularly for TNBC and basal-like BC.
    • Further research into these complex networks may significantly improve treatment strategies for breast cancer patients.
    Keywords:
    BRCA1BRCA2Breast cancerTNBCmiRNA

    More Related Videos

    Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

    Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

    Published on: February 21, 2014

    20.8K
    MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

    MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

    Published on: May 16, 2012

    25.1K

    Related Concept Videos

    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
    4.2K
    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
    24.5K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    5.0K
    lncRNA - Long Non-coding RNAs02:39

    lncRNA - Long Non-coding RNAs

    In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
    10.1K